Pharmafile Logo

Patients and data tracking

AstraZeneca AZ global R&D corporate HQ

AZ gets orphan status for selumetinib in thyroid cancer

Drug already in phase III testing for KRAS-mutant advanced NSCLC

Bayer symbol

Excess deaths cause Bayer to halt riociguat trial

No indication that Adempas may be unsafe in its approved uses

The difference between market intelligence and design intelligence

Blue Latitude Health's Elisa del Galdo explains how market and customer research differ, and in which situations you would use one over the other.

Blue Latitude Health

- PMLiVE

Coming to an understanding

EphMRA’s Dr Thomas Hein on how market research in pharma has been changing

The Missing Ingredient in Online Healthcare: Trust

By Brad Davidson, PhD, SVP Strategic Planning, Aptus Health

Aptus Health

Can Cinderella save us?

Hanover wins Steris account

Adds infection firm to its healthcare roster

Spirit Medical Communications

Spirit celebrates 10th anniversary with new divisions

Arc and Ascend will be based in Manchester and Alderley Park

National Institute for Health and Care Excellence NICE logo

NICE rejects Opdivo for lung cancer once again

Says PD-1 inhibitor is too expensive to be used routinely

- PMLiVE

Lucid Co-founder and COO discusses the changing landscape of healthcare communications

In May’s issue, Jan Steele (Lucid co-founder and COO) talks to PME about the importance of demonstrating value with medical education via validated improvements in patient outcomes. Jan explains that...

Lucid Group Communications Limited

Bristol-Myers Squibb (BMS) building

BMS gets two new cancer approvals in Europe

Empliciti, and Opdivo and Yervoy inhibitor combination get the green light

- PMLiVE

Lucid appoints trio of new starters

Laura Cunliffe, Cynthia Chen and Chloe Powell join the UK agency

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links